MYE0 Stock Overview
A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MaxCyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£3.64 |
| 52 Week High | UK£4.96 |
| 52 Week Low | UK£2.32 |
| Beta | 1.08 |
| 11 Month Change | -14.55% |
| 3 Month Change | -9.00% |
| 1 Year Change | -11.22% |
| 33 Year Change | -65.98% |
| 5 Year Change | n/a |
| Change since IPO | -50.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYE0 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -0.5% | 0.09% |
| 1Y | -11.2% | -14.4% | 3.1% |
Return vs Industry: MYE0 exceeded the German Life Sciences industry which returned -14.4% over the past year.
Return vs Market: MYE0 underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| MYE0 volatility | |
|---|---|
| MYE0 Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: MYE0's share price has been volatile over the past 3 months.
Volatility Over Time: MYE0's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 143 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
| MYE0 fundamental statistics | |
|---|---|
| Market cap | €397.24m |
| Earnings (TTM) | -€34.14m |
| Revenue (TTM) | €41.12m |
9.7x
P/S Ratio-11.6x
P/E RatioIs MYE0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYE0 income statement (TTM) | |
|---|---|
| Revenue | US$44.05m |
| Cost of Revenue | US$5.15m |
| Gross Profit | US$38.91m |
| Other Expenses | US$75.48m |
| Earnings | -US$36.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 88.32% |
| Net Profit Margin | -83.00% |
| Debt/Equity Ratio | 0% |
How did MYE0 perform over the long term?
See historical performance and comparison